Understanding how malaria parasites become resistant to drugs
Malaria parasites cause approximately 240 million infections each year, which results in approximately 608,000 deaths annually. There are drugs that help treat malaria infection and the current best treatments are artemisinin-based combination therapies.
Unfortunately, parasites are developing resistance to artemisinin. It is known that specific mutations in the Kelch-13 gene underpin artemisinin resistance phenotypes and one specific mutation in this gene, C580Y, has been linked with treatment failure throughout Southeast Asia.
Most of the global malaria disease burden is experienced by West Africa, where fortunately artemisinin resistance is not yet widespread and artemisinin-combination therapies remain effective treatment options.
Alarmingly however, novel African-specific mutations in Kelch-13 are being detected in East Africa and are expected to spread to West Africa in the next 5-7 years. As these mutations are different from those that have been well-defined in Southeast Asia, it is not yet known what effect they will have on artemisinin resistance.
This project is open to students
State-of-the-art molecular biology techniques
The project will seek to understand how these novel mutations will affect malaria parasites from West Africa. It will involve inserting these point mutations into the Kelch-13 gene into parasites of Africa origin and assessing if they engender artemisinin resistance.
This project will involve state-of-the-art molecular biology techniques with a variety of plate- and microscopy-based phenotypic assays. It will have a real-world impact as it will help predict the effect of these mutations in currently circulating parasite populations.
Open to
- Honours
- Masters by research
- PhD
Vacancies
6
Supervisors
Project contacts
Associate Professor Paul Gilson
Deputy Discipline Head, Life Sciences; Co-Head Malaria Virulence, Drug Discovery and Resistance; Head of Burnet Cell Imaging Facility
Dr Hayley Bullen
Co-Head Malaria Virulence, Drug Discovery and Resistance
Project team
Dr Hayley Bullen
Co-Head Malaria Virulence, Drug Discovery and Resistance
Associate Professor Paul Gilson
Deputy Discipline Head, Life Sciences; Co-Head Malaria Virulence, Drug Discovery and Resistance; Head of Burnet Cell Imaging Facility
Rachael Yong
PhD Student
More student projects
View 62 more
Protektem Pikinini Blong Yu: Preventing mother-to-child transmission of hepatitis B in Vanuatu
This field trial compares the effectiveness of WHO-based viral load testing guidelines to an alternative model of care.
Methamphetamine use in Melbourne and rural Victoria: the VMAX cohort study
The VMAX cohort study follows 850 people who use methamphetamine recruited from metropolitan Melbourne and 3 regions of rural Victoria.
Methamphetamine and injecting drug use cohort studies: MIXMAX
MIXMAX is the largest active cohort study of people who use drugs in Australia. It combines 2 pre-existing studies: SuperMIX and VMAX.